Affiliation:
1. Institute of Pharmacy, Nirma University S G Highway, Ahmedabad, Gujarat, India – 382481.
Abstract
In recent years, solid form screening has become an integral and mandatory part of drug development. Solid form screening typically involves producing and characterizingmaximum possible solid forms of a potential drug candidate. Different types of solid forms for future drug product development includes salt screening, co-crystal screening, crystallization process development, polymorph screening as well as amorphous solid dispersion screening.Screening studies of a solid form is a set of carefully designed experiments that requires use of advanced analytical techniques to collect analytical data followed by a thoughtful data analysis.This solid form screening studies guide an important decision-making of lead solid form whichis likely to play a vital role during the pharmaceutical product development lifecycle. The selection criteria include pharmaceutically relevant properties, such as therapeutic efficacy and processing characteristics as well as role of physicochemical properties (i.e. solubility, dissolution rate, hygroscopicity, physical stability and chemical purity) in drug product development. A selected solid form, if thermodynamically unstable, it may undergo solid form changes upon exposure to environmental conditions such as temperature and relative humidity as well as manufacturing stress during the pharmaceutical unit operations. In thepresent work, fundamentals of solid form screening are discussed, including the experimental screening methodologies as well as characterization and analysis of solid forms. The importance of drug product risk assessment pertaining to the desired solid form are also discussed here.
Publisher
Oriental Scientific Publishing Company
Subject
Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science
Reference111 articles.
1. Stahl, P. H.; Wermuth, C. G., Pharmaceutical salts: Properties, selection and use. John wiley & sons: 2002.
2. Huang, L.-F.; Tong, W.-Q. T., Impact of solid state properties on developability assessment of drug candidates. Advanced Drug Delivery Reviews 2004,56 (3), 321-334.
3. Ku, M., Salt and polymorph selection strategy based on the biopharmaceutical classification system for early pharmaceutical development. American Pharmaceutical Review 2010,13 (1), 22-30.
4. Davies, G., Changing the salt, changing the drug. Pharmaceutical Journal 2001,266 (7138), 322-323.
5. Byrn, S.; Pfeiffer, R.; Ganey, M.; Hoiberg, C.; Poochikian, G., Pharmaceutical solids: a strategic approach to regulatory considerations. Pharmaceutical Research 1995,12 (7), 945-954.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献